Author:
Zou Gang,Cao Sushan,Gao Zhao,Yie Junming,Wu Jim Zhen
Reference162 articles.
1. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children;Abarca;Pediatr. Infect. Dis. J.,2009
2. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults;Ackerson;Clin. Infect. Dis.,2019
3. EDP-938, a respiratory syncytial virus inhibitor, in a human virus challenge;Ahmad;N. Engl. J. Med.,2022
4. Occurrence of respiratory syncytial virus subtypes A and B strains in Sweden;Akerlind;J. Med. Virol.,1986
5. A phase 1 randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, and pharmacokinetics of a respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy adults;Aliprantis;Clin Pharmacol Drug Dev,2021